证券代码：601567 证券简称：三星医疗 公告编号：临 2024-103 宁波三星医疗电气股份有限公司 2024 年第四次临时股东大会决议公告 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 109 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 788,888,361 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 56.3618% | 注：上表中公司有表决权股份总数不含公司回购账户中的股份数，本次已剔除。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长沈国英女士主持，采用现场投票和 网络投票相结合的表决方式。会议召开符合《公司法》和《公司章程》的有关规 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 9 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company's performance in the first half of 2024 exceeded market expectations, driven by rapid growth in smart power distribution orders and accelerated development in overseas distribution business [3][4]. - The earnings per share (EPS) forecasts for 2024 and 2025 have been raised to 1.71 and 2.10 CNY respectively, with a target price set at 44.55 CNY based on a price-to-earnings (PE) ratio of 21.21x for 2025 [4][6]. Financial Performance Summary - In H1 2024, the company achieved revenue of 6.997 billion CNY, a year-on-year increase of 26.11%, and a net profit attributable to shareholders of 1.150 billion CNY, up 32.23% year-on-year [4][5]. - The second quarter of 2024 saw revenue of 3.972 billion CNY, a 20.37% increase year-on-year and a 31.34% increase quarter-on-quarter [4]. - The company’s smart power distribution business generated revenue of 5.316 billion CNY in H1 2024, reflecting a 27.2% year-on-year growth, with net profit reaching 0.971 billion CNY, up 29.37% year-on-year [4]. Business Segment Performance - The smart power distribution business has a backlog of orders amounting to 14.894 billion CNY, a 25.74% increase year-on-year, with significant growth in overseas markets [4]. - The medical services segment reported revenue of 1.613 billion CNY in H1 2024, a 26.53% increase year-on-year, with a focus on rehabilitation services [4]. Financial Projections - The company’s projected revenues for 2024, 2025, and 2026 are 14.373 billion CNY, 17.634 billion CNY, and 20.887 billion CNY respectively, with corresponding net profits of 2.411 billion CNY, 2.964 billion CNY, and 3.569 billion CNY [5][12]. - The net asset return (ROE) is expected to improve from 17.3% in 2023 to 22.8% in 2026 [5][12].

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 回购注销部分激励对象已获授但尚未解除限售的第四期、 第五期限制性股票实施情况的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 传真: 021-20511999 电话: 021-20511000 邮编: 210020 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于宁波三星医疗电气股份有限公司 回购注销部分激励对象已获授但尚未解除限售的第四期、第五期 关于宁波三星医疗电气股份有限公司 限制性股票实施情况的 法律意见书 致:宁波三星医疗电气股份有限公司 上海市锦天城律师事务所(以下简称"锦天城"或"本所") 接受宁波三星 医疗电气股份有限公司(以下简称"公司"或"三星医疗")的委托,担任公司 第四期限制性股票激励计划(以下简称"第四期激励计划")、第五期限制性股票 激励计划(以下简称"第五期激励计划")相关事宜的专项法律顾问。受公司委 托,根据《中华人民共和国公司法》(以下简称"《公司法》)、《中华人民共和国 证券法》(以下简称"《证 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-100 宁波三星医疗电气股份有限公司 主营业务：输电 是否与公司存在关联关系：公司及子公司与 Transmission Company of Nigeria 公 司不存在关联关系。 关于子公司签订海外经营合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 宁波三星医疗电气股份有限公司（以下简称"公司"）及其全资子公司宁波三星 智能电气有限公司（以下简称"三星智能"）中标尼日利亚 TCN（尼日利亚输电公司） 智能表总包项目，合同金额总计约合 4.93 亿人民币。具体情况如下： 一、交易概述 公司及三星智能在尼日利亚 TCN（尼日利亚输电公司）项目中中标智能表总包 项目，公司及三星智能作为供应商，提供电表、表箱、系统、安装及运维服务，合 同金额总计约合 4.93 亿人民币。 二、合同对方当事人情况 公司名称：Transmission Company of Nigeria 注册时间：2005 年 11 月 敬请广大投资者谨慎决策，注意防范 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-101 宁波三星医疗电气股份有限公司 关于股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：宁波三星医疗电气股份有限公司（以下简称"公司"）第 四期及第五期限制性股票激励计划中 10 名激励对象因离职已不符合激励条件， 其已获授但尚未解除限售的限制性股票由本公司回购注销。 本次注销股份的有关情况 | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 股 111,300 | 111,300 | 股 | 年 2024 9 | 月 | 日 6 | 期限制性股票激励计划激励对象名单的核查意见及公示情况说明》。 4、2021 年 12 月 3 日，公司召开 2021 年第二次临时股东大会，审议通过了 《关于第四期限制性股票激励计划（草案）及其摘要的议案》《关于第四期限制 性股票激励计划实施考核管理办法的议案》及《关于 ...

证券代码：601567 证券简称：三星医疗 宁波三星医疗电气股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-099 宁波三星医疗电气股份有限公司 关于经营合同预中标的提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司 董事会 宁波三星医疗电气股份有限公司（以下简称"公司"）于近日在国家电网有限公司 2024 年第六十四批采购（营销项目第二次计量设备招标采购）项目中被推荐为中标候 选人，预计合计中标总金额约为 14,345.31 万元，现将预中标情况公告如下： 一、国家电网项目预中标的主要内容 国家电网有限公司于近日在其电子商务平台（http://ecp.sgcc.com.cn）公告"国家 电网有限公司2024年第六十四批采购（营销项目第二次计量设备招标采购）推荐的中 标候选人公示"（招标编号：0711-24OTL08422014），公司为中标候选人。 根据公示内容，公司为此项目A级单相智能电能表、B级三相智能电能表、C级三 相智能电能表、高端智能电能表、集中器及采集器、专变采集终端的中标候选人，根 据公司预中标数量及报价测算，预计中标 ...

Investment Rating - The report maintains a "Buy" rating for the company, Samsung Medical [3]. Core Views - The company reported Q2 2024 earnings that exceeded expectations, with a revenue of 6.997 billion yuan, a year-on-year increase of 26.11%, and a net profit of 1.15 billion yuan, up 32.23% [1]. - The revenue for Q2 2024 was 3.973 billion yuan, reflecting a 20.37% year-on-year growth, while the net profit for the same period was 786 million yuan, increasing by 30.92% [1]. - The report highlights the growth potential in the overseas distribution and power supply business, with a focus on markets in the Middle East, Europe, and Latin America [1][2]. Financial Performance - The company's gross margin for H1 2024 increased by 3.49 percentage points to 34.61%, with Q2 2024 gross margin at 37.21%, up 5.6 percentage points year-on-year and 6.0 percentage points quarter-on-quarter [2]. - The net profit margin for H1 2024 rose by 0.76 percentage points to 16.49%, with Q2 2024 net profit margin at 19.88%, an increase of 1.69 percentage points year-on-year and 7.83 percentage points quarter-on-quarter [2]. - The report projects a slight upward adjustment in profit forecasts, estimating net profits of 2.45 billion yuan, 2.97 billion yuan, and 3.59 billion yuan for 2024, 2025, and 2026 respectively, representing year-on-year growth rates of 28.7%, 21.2%, and 20.8% [2][6]. Business Segments - In the smart power distribution segment, revenue for H1 2024 was 5.38 billion yuan, a 26% increase, with a net profit of 971 million yuan, growing by 29% [1]. - The medical services segment generated revenue of 1.613 billion yuan in H1 2024, up 27%, with a net profit of 183 million yuan, reflecting a 61% increase [1]. - The company has established production bases in Brazil, Indonesia, Poland, Germany, and Mexico, with overseas production capacity accounting for approximately 50% of total capacity [1].

2024 年 08 月 23 日 公司研究 评级：买入(维持) 证券分析师： 李航 S0350521120006 lih11@ghzq.com.cn 证券分析师： 王刚 S0350524020001 wangg06@ghzq.com.cn 研究所： [Table_Title] 配用电和医疗双轮驱动，海外配电持续获得突破 ——三星医疗（601567）2024 年半年报点评 最近一年走势 事件: 三星医疗 2024 年 8 月 23 日发布 2024 年半年度报告：2024H1，公司实 现营收 70 亿元，同比+26%；归母净利润 11.5 亿元，同比+32%；扣非 归母净利润 10.8 亿元，同比+32%；销售毛利率 34.6%，同比+3.5pct； 销售净利率 16.5%，同比+0.8pct。 其中，2024Q2，营收 40 亿元，环比+31%，同比+20%；归母净利润 7.9 亿元，环比+116%，同比+31%；扣非归母净利润 7.0 亿元，环比+87%， 同比+28%；销售毛利率 37.2%，环比+6.0pct，同比+5.6pct；销售净利 率 19.9%，环比+7.8pct，同比+1.7pct。 投资要 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [4][9] Core Views - The company has achieved significant revenue and profit growth in the first half of 2024, with revenue reaching 6.997 billion yuan, a year-on-year increase of 26.11%, and net profit of 1.15 billion yuan, up 32.23% year-on-year [5][8] - The company has successfully expanded its overseas distribution business, securing its first orders in the European and American markets, indicating a strong focus on high-end markets in the Middle East, Europe, and America [2][8] - The company has a robust order backlog, with total orders reaching 14.894 billion yuan, a year-on-year increase of 25.74%, including overseas orders of 6.22 billion yuan, up 40.47% year-on-year [8] Summary by Sections Financial Performance - In the first half of 2024, the company reported a revenue of 6.997 billion yuan, a 26.11% increase year-on-year, and a net profit of 1.15 billion yuan, reflecting a 32.23% year-on-year growth [5][8] - The gross profit margin for the first half of 2024 was 34.61%, an increase of 3.49 percentage points year-on-year, while the net profit margin was 16.49%, up 0.76 percentage points year-on-year [5][8] Operational Highlights - The company has established five overseas production bases in Brazil, Indonesia, Poland, Germany, and Mexico, with overseas production capacity accounting for approximately 50% of total capacity [8] - The company has made progress in the German market, securing small batch orders, and is upgrading automation in its Brazilian factory to enhance efficiency and reduce costs [8] Market Expansion - The company has focused on high-end markets, achieving its first distribution orders in Europe and America, including a 466 million yuan transformer project in Greece and a 79 million yuan transformer project in Mexico [2][8] - The company’s medical services segment also showed strong growth, with revenue of 1.613 billion yuan in the first half of 2024, a 26.53% increase year-on-year [8]